Literature DB >> 29223980

Behavioral Economics and the Future of Biosimilars.

Chadi Nabhan, Bruce A Feinberg.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29223980     DOI： 10.6004/jnccn.2017.7023

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  5 in total

1.  Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Authors:  Brian Chen; Sumimasa Nagai; James O Armitage; Bartlett Witherspoon; Chadi Nabhan; Ashley C Godwin; Y Tony Yang; Anuhya Kommalapati; Sri Harsha Tella; Carlo DeAngelis; Dennis W Raisch; Oliver Sartor; William J Hrushesky; Paul S Ray; Paul R Yarnold; Bryan L Love; LeAnn B Norris; Kevin Knopf; Laura Bobolts; Joshua Riente; Stefano Luminari; Robert C Kane; Shamia Hoque; Charles L Bennett
Journal:  Oncologist       Date:  2019-03-06

Review 2.  Informing Patients about Biosimilar Medicines: The Role of European Patient Associations.

Authors:  Yannick Vandenplas; Steven Simoens; Philippe Van Wilder; Arnold G Vulto; Isabelle Huys
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-04

3.  Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines.

Authors:  Arnold G Vulto; Isabelle Huys; Yannick Vandenplas; Steven Simoens; Florian Turk
Journal:  Appl Health Econ Health Policy       Date:  2022-08-16       Impact factor: 3.686

4.  Barriers to Oncology Biosimilars Uptake in the United States.

Authors:  Chadi Nabhan; Amy Valley; Bruce A Feinberg
Journal:  Oncologist       Date:  2018-07-26

5.  Biosimilar Uptake: The Importance of Healthcare Provider Education.

Authors:  Sonia Tadjalli Oskouei; Andrew R Kusmierczyk
Journal:  Pharmaceut Med       Date:  2021-08-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.